跳至主要内容
临床试验/CTRI/2025/08/092540
CTRI/2025/08/092540已完成不适用

A Clinical study to evaluate the effect of Holistic Shatavari as complete women Healthcare

Zeroharm Sciences Private Limited1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年8月18日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
The patient will be assessed based on their improvement in symptoms using a menstrual cycle scoring system

研究概览

简要总结

A clinical study will be conducted to evaluate the efficacy and safety of Holistic Shatavari, an Ayurvedic formulation, in promoting women’s health and well-being.

Eligible participants will receive Zeroharm Holistic Shatavari tablets daily for three months.

Two follow-up visits will be scheduled at monthly intervals to assess progress.

Laboratory investigations will be performed before and after the treatment to measure improvements.

Key health indicators will include hormonal levels, menstrual health, energy, and mood balance.

Patient-reported outcomes and symptom assessments will be recorded throughout the study.

The study will also monitor for any adverse effects or safety concerns.

Compliance and tolerability of the Ayurvedic formulation will be evaluated.

All collected data will undergo statistical analysis to determine efficacy.

This study aims to scientifically validate Holistic Shatavari as a natural support for women’s wellness.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
Female

入选标准

  • Patients with the chief complaint of Dysmenorrhoea/Menorrhagia for atleast 3 cycles Subjects not suffering from any significant illness (medical / surgical) Subjects willing to follow the procedures as per the study protocol and voluntarily sign an informed consent form.

排除标准

  • Subjects below 18 years or above 60 years of age.
  • Patients suffering from acute infections.
  • Pregnant or breast feeding women.

结局指标

主要结局

The patient will be assessed based on their improvement in symptoms using a menstrual cycle scoring system

时间窗: 12 weeks

次要结局

  • Investigations: Bloodroutine, RBS, FSH,LH, Progesterone levels(12 weeks)

研究者

发起方
Zeroharm Sciences Private Limited
申办方类型
Other [Neutracutical Company ]
责任方
Principal Investigator
主要研究者

Dr kaushalya khakhlary

Government Ayurvedic College, Jalukbari, Guwahati -14 , Assam

研究点 (1)

Loading locations...

相似试验